Results 41 to 50 of about 209,011 (190)

Natural Bioactive Compounds from Fungi as Potential Candidates for Protease Inhibitors and Immunomodulators to Apply for Coronaviruses

Molecules, 2020
The inhibition of viral protease is an important target in antiviral drug discovery and development. To date, protease inhibitor drugs, especially HIV-1 protease inhibitors, have been available for human clinical use in the treatment of coronaviruses ...
Nakarin Suwannarach, Jaturong Kumla, Kanaporn Sujarit, Thanawat Pattananandecha, Chalermpong Saenjum, Saisamorn Lumyong   +5 more
doaj   +1 more source

Endourological management of a rare radiopaque ritonavir-composed urinary calculus

Urology Case Reports, 2021
Protease inhibitors are a source of nephrolithiasis in HIV + patients, and these stones are described as not detected by CT. While urinary stones are commonly associated with certain protease inhibitors, stones composed of ritonavir are rare.
Folawiyo Laditi, Amir Ishaq Khan, Eric M. Ghiraldi, Tashzna Jones, Ankur Choksi, Dinesh Singh   +5 more
doaj   +1 more source

Suppression of Preadipocyte Differentiation and Promotion of Adipocyte Death by HIV Protease Inhibitors*

Journal of Biological Chemistry, 2000
Many human immunodeficiency virus (HIV)-infected patients taking combination antiretroviral therapy that includes HIV protease inhibitors experience atrophy of peripheral subcutaneous adipose tissue. We investigated the effects of HIV protease inhibitors
P. Dowell, C. Flexner, P. Kwiterovich, M. Lane   +3 more
semanticscholar   +1 more source

THE DESIGN, MODELING AND EVALUATION OF POTENTIAL HIV PROTEASE INHIBITORS USING BLITZ, AN INTERACTIVE COMPUTER GRAPHICS WORKING TOOL [PDF]

Journal of Sciences, Islamic Republic of Iran, 1996
Several nonpeptide small molecules were designed as potential inhibitors of HIV protease and their structures were constructed by computer-aided molecular modeling and docked iwo the active site of HIV protease.
doaj  

Commentary on the role of treatment-related HIV compensatory mutations on increasing virulence: new discoveries twenty years since the clinical testing of protease inhibitors to block HIV-1 replication

BMC Medicine, 2012
Approximately 20 years has passed since the first human trial with HIV-1 protease inhibitors. Protease inhibitors set the stage for combination therapy in the mid-1990s but are now rarely used in first-line combination therapy and reserved for salvage ...
Arts Eric J
doaj   +1 more source

HIV Drug Resistance Mutations in Patients with HIV and HIV-TB Coinfection After Failure of First-Line Therapy: A Prevalence Study in a Resource-Limited Setting

Journal of the International Association of Providers of AIDS Care, 2019
Introduction: The present study aimed to report the prevalent HIV-1 drug-resistant mutations in patients with HIV-1 alone and tuberculosis (TB) coinfection alone to improve our understanding of the mutation patterns and aid treatment decisions.
Nawaid Hussain Khan PhD, Mikashmi Kohli PhD, Kartik Gupta MD, Bimal Kumar Das MD, Ravindra Mohan Pandey PhD, Sanjeev Sinha MD   +5 more
doaj   +1 more source

Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment

Virology Journal, 2012
Background Development of compensatory mutations within the HIV p7/p1 and p1/p6 protease cleavage site region has been observed in HIV-infected patients treated with protease inhibitors.
Sullivan James C, Zhang Eileen Z, Bartels Doug J, Tigges Ann, Dorrian Jennifer L, Kwong Ann D, Kieffer Tara L   +6 more
doaj   +1 more source

Synthesis and characterization of gold(I) thiolate derivatives and bimetallic complexes for HIV inhibition

Frontiers in Chemistry
Introduction: The human immunodeficiency virus (HIV) remains a significant global health concern, with a reported high infection rate of 38.4 million cases globally; an estimated 2 million new infections and approximately 700,000 HIV/AIDS-related deaths ...
Christian K. Adokoh, Akwasi Boadu, Akwasi Boadu, Isaac Asiamah, Clement Agoni   +4 more
doaj   +1 more source

Analysis of drug resistance in HIV protease

BMC Bioinformatics, 2018
Background Drug resistance in HIV is the major problem limiting effective antiviral therapy. Computational techniques for predicting drug resistance profiles from genomic data can accelerate the appropriate choice of therapy. These techniques can also be
Shrikant D. Pawar, Christopher Freas, Irene T. Weber, Robert W. Harrison   +3 more
doaj   +1 more source

Select HIV Protease Inhibitors Alter Bone and Fat Metabolismex Vivo *

Journal of Biological Chemistry, 2002
Human immunodeficiency virus (HIV) therapies have been associated with alterations in fat metabolism and bone mineral density. This study examined the effects of HIV protease inhibitors (PIs) on bone resorption, bone formation, and adipocyte ...
Renu G Jain, J. Lenhard
semanticscholar   +1 more source